BAXHealthcare · Medical Instruments & SuppliesThe 13 Wall Street analysts covering Baxter International, Inc. hold a median 12-month price target of $28 — +14.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Baxter International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (49): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.8% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | Citigroup | Upgrade | Neutral | $17 → $28 |
| 31 July 2026 | Stifel | Maintains | Hold | $24 → $28 |
| 31 July 2026 | TD Cowen | Maintains | Hold | $24 → $29 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $19 → $23 |
| 28 July 2026 | Stifel | Maintains | Hold | $19 → $24 |
| 28 July 2026 | UBS | Maintains | Neutral | $19 → $25 |
| 27 July 2026 | TD Cowen | Maintains | Hold | $20 → $24 |
| 15 July 2026 | Goldman Sachs | Maintains | Neutral | $19 → $21 |
| 15 July 2026 | Goldman Sachs | Maintains | Neutral | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $22 → $24 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 28 May 2026 | Citigroup | Downgrade | Sell | — |
| 4 May 2026 | Barclays | Maintains | Overweight | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 11 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 17 Feb 2026 | Goldman Sachs | Maintains | Neutral | — |
| 13 Feb 2026 | Barclays | Maintains | Overweight | — |
| 9 Jan 2026 | Barclays | Maintains | Overweight | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Underweight | — |
| 31 Oct 2025 | Argus Research | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BAX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Sept 2026, Baxter International, Inc. returned −0.1% against +18.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 68% of US stocks
Cheaper than 45% of US stocks
Cheaper than 35% of US stocks
Higher than 39% of US stocks
Higher than 71% of US stocks
Higher than 42% of US stocks
Higher than 72% of US stocks
Higher than 20% of US stocks
Higher than 34% of US stocks
Higher than 64% of US stocks
Higher than 2% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Baxter International, Inc. has a market value of $13.4B and an enterprise value of $20.8B.
Revenue in the twelve months to 30 June 2026: $11.5B. The latest quarter grew 5.3% year on year.
Net income over the same four quarters: −$1.1B, a −9.3% net margin.
Diluted earnings per share, trailing twelve months: $−2.07.
Free cash flow in the twelve months to 30 June 2026: $812.0M, after $504.0M of capital spending.
Baxter International, Inc. spent $184.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 86.3×; forward P/E: 12.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.16%, paying out 308% of earnings.
Baxter International, Inc. employs 37,500 people — $306K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Baxter International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Baxter International presented at the Wells Fargo 21st Annual Healthcare Conference, with Seeking Alpha publishing the transcript of the presentation.
Why it matters — The transcript provides BAX watchers with direct insight into the company's commentary and positioning shared at a major industry investor conference.
Baxter raised its 2026 sales and earnings outlook after strong second-quarter growth. Manufacturing costs, tariffs, and pricing pressures are noted as factors pressuring margins.
Why it matters — A BAX watcher would care because the raised 2026 outlook signals confidence in continued revenue growth, even as cost and tariff pressures could weigh on profitability.
Baxter International announced the appointment of John Rogers as executive vice president and chief financial officer, effective Oct. 1, 2026. Rogers will report to Baxter president and CEO Andrew Hider.
Why it matters — A BAX watcher would care because the appointment of a new CFO, described as a proven global finance executive with transformation experience, signals a change in the company's senior financial leadership.
Baxter International announced the pricing terms for its previously announced cash tender offers for certain of its notes, using a "waterfall" methodology under which the Company will accept validly tendered notes in order of their respective acceptance priority levels. The offers were upsized from their initial size.
Why it matters — The tender offers reflect Baxter's debt-management activity, which Baxter watchers would track for its potential impact on the company's capital structure and liabilities.
Baxter International announced the early results of its previously announced cash tender offers for certain notes, which were made pursuant to an Offer to Purchase dated Aug. 4, 2026. The company also reported an upsizing of the tender offers.
Why it matters — The tender offer results and upsizing reflect Baxter's ongoing debt-management activities, which are relevant to investors tracking the company's capital structure.
The 13 Wall Street analysts covering Baxter International, Inc. have a median 12-month price target of $28, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Baxter International, Inc., 2 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Baxter International, Inc. 91 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Sept 2026, Baxter International, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +14.8% from the last close, and Ticker Nerd's factor model ranks Baxter International, Inc. 91 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Baxter International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.
Baxter International, Inc. returned -0.1% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings.
The most recent item we track (Seeking Alpha, 9 Sept 2026): "Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript". Baxter International presented at the Wells Fargo 21st Annual Healthcare Conference, with Seeking Alpha publishing the transcript of the presentation.
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.
CEO Mr. Andrew P. Hider · 37,500 employees · United States · https://www.baxter.com
